Note: All changes are versus the prior-year period unless otherwise stated
Daiichi Sankyo stated that it achieved growth with "mainstay products" such as Enhertu and Lixiana, as well as the recognition of JPY 1 billion ($10 million) in revenue from an upfront payment by AstraZeneca regarding their global collaboration on TROP2-directed antibody-drug conjugate DS-1062. However, the Japanese drugmaker noted that quarterly revenues remained about level with the year-ago period as a result of the effects of the COVID-19 pandemic, as well as drug price revisions in Japan and the termination of a vaccine sales cooperation.
For the fiscal year ending March 2021, Daiichi Sankyo now anticipates revenues of JPY 960 billion ($9.2 billion) and profit of JPY 53 billion ($507 million). The drugmaker had previous forecast sales of JPY 970 billion ($9.3 billion), while profit was estimated at JPY 56 billion ($536 million).
To read more Top Story articles, click here.